Header Logo

Connection

JOHN KIRKWOOD to MAP Kinase Kinase 2

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about MAP Kinase Kinase 2.
JOHN KIRKWOOD
Connection Strength
0.098
MAP Kinase Kinase 2
  1. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):555-67.
    View in: PubMed
    Score: 0.098
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.